Advances in the clinical and translational applications of breast cancer organoids

doi:10.3760/cma.j.cn371439-20250110-00064

Abstract

Abstract:

Breast cancer organoids faithfully reflect the structural and functional characteristics of primary tumors， demonstrating broad application potential. Clinically， organoids have been utilized for drug sensitivity testing， significantly enhancing the precision of personalized treatment strategies. Organoids play a crucial role in accelerating new drug development， uncovering drug resistance mechanisms， and improving the efficacy of immunotherapy. In-depth analysis of the application of breast cancer organoid technology in clinical and transformation can provide new ideas for clinical diagnosis and treatment of breast cancer.

Key words: Breast neoplasms, Organoids, Drug evaluation， preclinical, Precision medicine

Li Lixi, Duan Boshi, Qian Haili, Ma Fei. Advances in the clinical and translational applications of breast cancer organoids[J]. Journal of International Oncology, 2025, 52(6): 379-381.

References 23

[1]	Tuveson D, Clevers H. Cancer modeling meets human organoid technology[J]. Science, 2019, 364(6444): 952-955. DOI: 10.1126/science.aaw6985. pmid: 31171691
[2]	Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019, 25(5): 838-849. DOI: 10.1038/s41591-019-0422-6. pmid: 31011202
[3]	Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1/2): 373-386.e10. DOI: 10.1016/j.cell.2017.11.010.
[4]	Rosenbluth JM, Schackmann RCJ, Gray GK, et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages[J]. Nat Commun, 2020, 11(1): 1711. DOI: 10.1038/s41467-020-15548-7.
[5]	Chen P, Zhang X, Ding R, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer[J]. Adv Sci (Weinh), 2021, 8(22): e2101176. DOI: 10.1002/advs.202101176.
[6]	Lin YY, Gao HF, Li H, et al. Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer[J]. Int J Cancer, 2024, 155(4): 697-709. DOI: 10.1002/ijc.34945.
[7]	Shu D, Shen M, Li K, et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy[J]. Ann Med, 2022, 54(1): 2581-2597. DOI: 10.1080/07853890.2022.2122550. pmid: 36194178
[8]	Ye HS, Zhou D, Li H, et al. Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy[J]. Br J Cancer, 2024, 130(7): 1109-1118. DOI: 10.1038/s41416-024-02595-w.
[9]	Beelen NA, Aberle MR, Bruno V, et al. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids[J]. Front Immunol, 2023, 14: 1133796. DOI: 10.3389/fimmu.2023.1133796.
[10]	Jiang S, Deng T, Cheng H, et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance[J]. J Exp Clin Cancer Res, 2023, 42(1): 199. DOI: 10.1186/s13046-023-02756-4.
[11]	Ou L, Liu S, Wang H, et al. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies[J]. EBioMedicine, 2023, 92: 104614. DOI: 10.1016/j.ebiom.2023.104614.
[12]	Xu NY, Li J, Wang ML, et al. Fabrication of a coculture organoid model in the biomimetic matrix of alginate to investigate breast cancer progression in a TAMs-leading immune microenvironment[J]. ACS Appl Mater Interfaces, 2024, 16(9): 11275-11288. DOI: 10.1021/acsami.3c17863.
[13]	Guillen KP, Fujita M, Butterfield AJ, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology[J]. Nat Cancer, 2022, 3(2): 232-250. DOI: 10.1038/s43018-022-00337-6.
[14]	Mao Y, Wang W, Yang J, et al. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids[J]. Protein Cell, 2024, 15(4): 285-304. DOI: 10.1093/procel/pwad038.
[15]	Chen B, Song Y, Zhan Y, et al. Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway[J]. Cancer Lett, 2022, 543: 215783. DOI: 10.1016/j.canlet.2022.215783.
[16]	Ye HS, Gao HF, Li H, et al. Higher efficacy of resveratrol against advanced breast cancer organoids: a comparison with that of clinically relevant drugs[J]. Phytother Res, 2022, 36(8): 3313-3324. DOI: 10.1002/ptr.7515.
[17]	Mo H, Liu X, Xue Y, et al. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer[J]. Mol Cancer, 2022, 21(1): 171. DOI: 10.1186/s12943-022-01642-5.
[18]	Arshad M, Azad A, Chan PYK, et al. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models[J]. Br J Cancer, 2024, 130(12): 1990-2002. DOI: 10.1038/s41416-024-02665-z.
[19]	Duarte AA, Gogola E, Sachs N, et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance[J]. Nat Methods, 2018, 15(2): 134-140. DOI: 10.1038/nmeth.4535. pmid: 29256493
[20]	Ding K, Chen F, Priedigkeit N, et al. Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine[J]. Ann Oncol, 2022, 33(10): 1085-1088. DOI: 10.1016/j.annonc.2022.06.005. pmid: 35764274
[21]	Chew NJ, Lim Kam Sian TCC, Nguyen EV, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models[J]. Breast Cancer Res, 2021, 23(1): 82. DOI: 10.1186/s13058-021-01461-4.
[22]	Michels BE, Mosa MH, Streibl BI, et al. Pooled in vitro and in vivo CRISPR-Cas9 screening identifies tumor suppressors in human colon organoids[J]. Cell Stem Cell, 2020, 26(5): 782-792.e7. DOI: 10.1016/j.stem.2020.04.003.
[23]	Lo YH, Kolahi KS, Du Y, et al. A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and nonessential modes of oncogenic transformation[J]. Cancer Discov, 2021, 11(6): 1562-1581. DOI: 10.1158/2159-8290.CD-20-1109.